Sie sind nicht angemeldet! Dieses Tagebuch ist öffentlich einsehbar und wird demnächst zurückgesetzt.
 | |||||||
| |||||||
| © tratabu.de
© tratabu.de
|
Dividendenzahlungen |
|||
| Titel | Ex-Datum | Zahldatum | Bruttobetrag |
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 21.07.25 09:50:00 | Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance |  |
| HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged. For the current fiscal year, the Company expects Group revenues in the range of €760-800m (previously: € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of €40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA is expected to reach €30-50m (unchanged; 2024: € 22.6 m). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth. - End of the ad hoc release - Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 1940 5058 (m), volker.braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 09.07.25 14:48:43 | Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes | |
| Sernova (SVA.TO) on Wednesday said it signed a collaborative research agreement with Eledon Pharmace PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in |
||
| 09.07.25 14:31:29 | Here Is What You Need To Know Before Investing In Evotec SE (EVO) |  |
| Evotec SE (NASDAQ:EVO) is among the 13 Best German Stocks to Invest in Now. The company’s shares have gained over 9% in the past month, as of the close of business on July 2, amid positive recent developments.Here Is What You Need To Know Before Investing In Evotec SE (EVO) A technician recording data from a complex experiment involving pharmaceutical products. On June 25, Evotec SE (NASDAQ:EVO) announced that it had joined the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches. Under this initiative, the company will identify key factors that cause AKI and develop innovative and effective treatments for patients based on a molecular understanding of the disease. Earlier in the month, Evotec SE (NASDAQ:EVO) held its annual general meeting for 2025, in which shareholders approved, with a great majority, most of the proposals put forward by the management. Around 46.45% of the registered share capital was represented in the meeting, in which CEO Dr Christian Wojczewski also discussed the company’s current situation and strategic outlook. Investor sentiment has also been strengthened by Warburg Research’s recent coverage of the stock on June 26, in which analyst Robert-Jan van der Horst reiterated a Buy rating for Evotec SE (NASDAQ:EVO), with its price target at €11.30. Evotec SE (NASDAQ:EVO) is a drug discovery company that focuses on developing new pharmaceutical products through the integration of breakthrough science, advanced technology, and AI-driven innovation. In May this year, it received a $2.5 million grant from the Gates Foundation to support the development of next-generation tuberculosis treatments. While we acknowledge the potential of EVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now. Disclosure: None. View Comments |
||
| 29.06.25 07:03:36 | Evotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug Discovery | |
| Evotec SE (NASDAQ:EVO) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company said it would participate in the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches.Evotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug Discovery A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. The NURTuRE-AKI consortium aims to establish the world’s largest patient cohort database for AKI with twofold objectives: to enhance understanding of its molecular mechanisms and accelerate drug discovery. The consortium is supported by £4.7 million from industry partners, including Evotec, AstraZeneca (NASDAQ:AZN), and Nephrolyx GmbH, facilitated by Kidney Research UK. Professor Nick Selby, a key researcher, oversees the AKI research efforts within the NURTuRE initiative. Besides helping fund the consortium, Evotec will integrate the consortium’s data into its proprietary E.MPD platform. The company will also conduct state-of-the-art omics analyses to identify core biological mechanisms, molecular targets, and biomarkers for AKI. Ultimately, the partnership enables Evotec to conduct targeted drug discovery by leveraging molecular insights into the progression of AKI. Evotec SE (NASDAQ:EVO) is a German biotechnology company. It operates as a drug discovery and development partner for pharmaceutical and biotech firms worldwide. Its two main segments are Shared R&D, which offers integrated research services, and Just–Evotec Biologics, which provides biologics development and manufacturing. While we acknowledge the potential of EVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. View Comments |
||
| 25.06.25 13:17:33 | Sector Update: Health Care Stocks Mixed Premarket Wednesday | |
| Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in |
||
| 25.06.25 05:50:00 | Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury | |
| NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI. This partnership will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI. HAMBURG, DE / ACCESS Newswire / June 25, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has joined the NURTuRE-AKI consortium for establishing a patient cohort for acute kidney injury (AKI), NURTuRE-AKI. This initiative will enable Evotec to identify key mechanisms that trigger AKI and to support the discovery of highly innovative treatments for AKI patients based on a molecular understanding of the disease. NURTuRE-AKI focuses on adult and pediatric cardiac surgery patients who are at high risk of developing AKI as well as patients undergoing AKI-to-CKD progression. The longitudinal study design includes biological sampling and clinical data collection at multiple time points for each patient. Blood, urine and research biopsy samples will be subjected to state-of-the-art omics analyses, forming the most comprehensive patient cohort for AKI and AKI-to-CKD worldwide. NURTuRE-AKI will be integral to Evotec's Molecular Patient Database (E.MPD), a repository of high-quality multi-omics data (PanOmics) and detailed clinical records. This new addition will further enhance Evotec's understanding of human diseases and expand its capabilities in precision medicine, drug discovery and development programs. "NURTuRE-AKI will unlock the identification of novel therapeutic targets and biomarkers based on comprehensive molecular and clinical patient data. This will accelerate the development of targeted therapies for a disease with a high unmet medical need, providing immense benefits for millions of patients worldwide", said Dr Cord Dohrmann, Chief Scientific Officer of Evotec . "We are extremely thrilled to be a vital part of this unique venture, which marks a significant step for Evotec in expanding its leadership in kidney disease drug discovery. To fully realize the potential of this initiative, we are actively seeking partners who share our commitment to transforming kidney disease treatment." Story Continues "Kidney Research UK are delighted to be partnering with Evotec and our other collaborators to develop NURTuRE-AKI, which will form a crucial resource for future research and innovation. We are already seeing important new findings from the initial NURTuRE CKD and INS cohorts and are confident that this venture has similarly great potential to change diagnosis and care for kidney disease patients." Elaine Davies, Director of research operation Kidney Research UK . About Acute Kidney Injury AKI is a sudden decline in kidney function, associated with an increased risk of mortality and a leading cause of chronic kidney disease (CKD). Major causes of AKI include alterations in blood pressure and the use of contrast agents for angiography, occurring during cardiac surgeries. Currently, there are no preventive or therapeutic treatments for AKI. About Kidney Research UK Kidney Research UK is the leading charity dedicated to funding research into the prevention, treatment and management of kidney disease. Led by the patient voice, we have spent over 60 years working with clinicians, scientists and partners across sectors to drive innovation and improve lives - investing £71 million in research over the last decade alone. Our vision is the day when everyone lives free from kidney disease. Find out more at www.kidneyresearchuk.org . About NURTuREand NURTuRE-AKI NURTuRE is a unique resource for the kidney disease community, accelerating discovery of new treatments and diagnostic approaches through secure provision of a rich resource of biological samples and data. The initial cohorts comprised 3,000 individuals with CKD and 740 with idiopathic nephrotic syndrome (INS). With the development of NURTuRE-AKI, this resource will be extended to include samples and data from AKI patients included in three sub cohorts. The first sub cohort comprises 400 adult individuals undergoing cardiac surgery with cardiopulmonary bypass. The risk of AKI incidence in this setting is approximately 30%, and there are currently 2 million open-heart surgeries per year worldwide. The second sub cohort will be formed by 150 pediatric cardiac surgery patients, and the third sub cohort 400 adult patients with persistent decline of renal failure indicating AKI to CKD progression. The study will run over a three-year period, the samples will be obtained through 13 NHS Trusts, with patients followed up at specific intervals. In addition to the samples of plasma, serum, urine, DNA and tissue, NURTuRE-AKIwill also have the considerable advantage of containing associated linked clinical data, through the UK Renal Registry. NURTuRE-AKI is funded by Evotec, AstraZeneca, Nephrolyx and Kidney Research UK. Experts from the Leeds Teaching Hospital NHS Trust, University of Bristol and University Hospital Birmingham form the core academic team overseeing all operational delivery. More information is available here: www.nurturebiobank.org . About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Media Susanne Kreuter VP Head of Strategic Marketing Susanne.Kreuter@evotec.com Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 07.05.25 07:06:22 | Evotec SE (EVO) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Embracing ... | |
| Group Revenue: EUR200 million, a 4% decrease versus Q1 2024. Shared R&D Revenue: EUR140.6 million, down from EUR155.2 million in Q1 2024. Just Evotec Biologics Revenue: EUR59.4 million, showing strong growth. Adjusted Group EBITDA: EUR3.1 million. Operating Cash Flow: Improved versus prior year due to favorable changes in working capital. CapEx Spending: EUR18 million in Q1 2025, a reduction from Q1 2024. Liquidity: Decreased by EUR26 million to EUR371 million by end of March 2025. Net Debt: Increased to EUR107 million, with a net debt leverage of 5.97 times adjusted. Full Year 2025 Guidance: Group revenues of EUR840 million to EUR880 million, R&D expenditure of EUR40 million to EUR50 million, and adjusted EBITDA of EUR30 million to EUR50 million. Warning! GuruFocus has detected 4 Warning Signs with EVO. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Evotec SE (NASDAQ:EVO) has made significant progress in its protein degradation collaboration with BMS, showcasing its strategy of technology leadership. The company received a grant from the Korean government to develop novel antibody treatments for lung fibrosis, highlighting its capabilities in drug discovery. Just Evotec Biologics delivered strong growth in Q1 2025, with revenues slightly ahead of expectations. Evotec SE (NASDAQ:EVO) is leveraging cutting-edge technology and AI-driven innovation to accelerate drug discovery and improve success probabilities. The company has implemented significant cost-saving measures, including site closures and headcount reductions, which are expected to positively impact future financials. Negative Points Evotec SE (NASDAQ:EVO) experienced a 4% decrease in group revenues in Q1 2025 compared to Q1 2024, primarily due to a decline in shared R&D revenue. The market for shared R&D remains soft, resulting in revenue decline and performance slightly below expectations. The company faces temporary lower BMS revenue, which is expected to continue in the midterm. Evotec SE (NASDAQ:EVO) has a temporarily elevated net debt leverage, with a net debt of EUR107 million. The company is operating in a cautious market environment with conservative spending from clients, impacting revenue growth. Q & A Highlights Q: Given the deviation in segment performance, with shared R&D underperforming and Just Evotec Biologics (JEB) overperforming, do you expect this trend to persist? Also, how might biotech and pharma layoffs impact your CRO activities? A: (Christian Wojczewski Wojczewski, CEO) The guidance remains unchanged as the overall revenue is balanced by the performance of both segments. The shared R&D market remains soft, but we are confident in our guidance. Layoffs in biotech and pharma could lead to more CRO activities as companies outsource work. Story Continues Q: Can you provide details on your pipeline for Just Evotec Biologics and shared R&D, particularly regarding customer and product concentration? Also, what are the details of your covenant waiver and working capital improvements? A: (Christian Wojczewski Wojczewski, CEO & Paul Hitchin, CFO) Customer concentration peaked in 2023-2024 but has since softened. We have a covenant waiver until Q3 2025, with testing in Q4. Working capital improvements are expected from BMS payments and Just-related work orders. Q: What gives you confidence in a recovery for shared R&D in the second half of the year? How do future BMS work packages factor into this? A: (Christian Wojczewski Wojczewski, CEO) Conversations with clients remain positive, though spending is cautious. BMS work packages are part of a large, multi-year program with varying revenue profiles, contributing to long-term growth. Q: Regarding Just Evotec Biologics, how will the ramp-up costs for Toulouse be phased over the year? A: (Paul Hitchin, CFO) The first quarter was stronger than expected, and ramp-up costs will continue throughout the year to support future growth. Q: How might potential cuts to NIH funding in the US impact Evotec, and could this create opportunities for you? A: (Christian Wojczewski Wojczewski, CEO) Our exposure to NIH is limited, so direct impact is minimal. We are prepared to serve clients in the US with our facilities, but the situation remains dynamic. Q: With the FDA's intention to phase out animal testing for biologics, how is Evotec positioned to adapt to these changes? A: (Paul Hitchin, CFO) Evotec is well-positioned with patient-centric approaches, iPSC technology, and PanOmics. The FDA's announcement is welcome, and we expect increased traction in discussions about these technologies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments |
||
| 18.04.25 07:01:31 | Evotec SE (EVO) (Q4 2024) Earnings Call Highlights: Strong Q4 Performance and Strategic ... | |
| Group Revenue: EUR797 million, a 2% increase versus 2023. Shared R&D Revenue: Declined from EUR673 million in 2023 to EUR611 million in 2024. Just - Evotec Biologics Revenue: EUR185.6 million in 2024, up from EUR108.4 million in 2023, a growth of 71%. R&D Spending: Reduced by 26% from EUR68.5 million in 2023 to EUR50.9 million in 2024. Adjusted EBITDA: EUR22.6 million for 2024. Q4 Revenue: EUR221.2 million, a 20% increase versus the third quarter. Q4 Gross Margin: Improved to 20.8%. Q4 Adjusted EBITDA: EUR28.5 million, a EUR33 million uplift versus the prior quarter. Operating Cash Flow: EUR74.2 million in the fourth quarter. Total Liquidity: Increased by EUR94 million versus third quarter, leading to a year-end balance of EUR397 million. Net Debt: Improved to EUR43 million with a net debt leverage of 1.9 times. Priority Reset Savings: EUR40 million of run rate savings to be fully P&L visible in 2025. Headcount Reduction: Approximately 280 completed role reductions by the end of 2024. Warning! GuruFocus has detected 5 Warning Signs with EVO. Release Date: April 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Evotec SE (NASDAQ:EVO) reported strong Q4 2024 results, marking the second-best quarter ever in terms of revenue, with significant operational leverage. The company successfully strengthened partnerships with major players like Sandoz, Bristol Myers Squibb, Novo Nordisk, Pfizer, and Bayer, paving the way for long-term growth. Just - Evotec Biologics saw a 71% revenue growth in 2024, driven by a strong order book and new deals. Evotec SE (NASDAQ:EVO) implemented a priority reset, achieving EUR40 million in run rate savings, which will be fully visible in 2025. The company is focusing on technology and science leadership, leveraging AI and next-generation technologies to enhance drug discovery and development processes. Negative Points Shared R&D revenue declined from EUR673 million in 2023 to EUR611 million in 2024 due to a persisting soft market. The company faced a challenging year with a high fixed cost base and slow market demand for its R&D segment. Evotec SE (NASDAQ:EVO) anticipates continued softness in the biopharma market throughout 2025, with a potential tipping point for growth not expected until the second half of the year. The company is not planning to invest in a new J.POD facility during the current planning horizon, indicating a cautious approach to capital expenditure. There are concerns about the indirect impact of potential budget cuts in the US on innovation and the biotech industry, which could affect future growth. Story Continues Q & A Highlights Q: What is the sustainable level of income tax credits or R&D tax credits for Evotec, and are there any risks to these credits? A: Paul Hitchin, CFO, stated that the tax credits are expected to grow in line with business growth and where R&D work is performed. Currently, there are no perceived risks to these credits. Q: Can you provide more details about the composition of Evotec's drug portfolio, specifically the phase composition of the 100 products? A: Cord Dohrmann, Chief Scientific Officer, explained that there are six assets in clinical stages and six in preclinical stages. Over the next 24 months, about 15 assets have the potential to move from preclinical to clinical stages. Q: How sophisticated are the models for phasing out animal testing, and is it possible to eliminate animal testing in the foreseeable future? A: Cord Dohrmann noted that Evotec is well-positioned to support the FDA's initiative to phase out animal testing. The company has developed advanced human microphysiological systems and AI-based approaches, which are expected to significantly improve predictive accuracy. Q: What are the growth drivers for Just - Evotec Biologics over the next 12 to 18 months, and how de-risked are these drivers? A: Christian Wojczewski, CEO, mentioned that there is high confidence in the growth of Just - Evotec Biologics due to pre-commitments from partners like Sandoz and a strong customer base developed over the last two years. Q: What is the synergy between Evotec's divisions, and what was the rationale for owning these businesses? A: Christian Wojczewski explained that the synergy lies in technology and science leadership, enabling partners to succeed. Shared R&D focuses on small molecules, while Just - Evotec Biologics focuses on large molecules, both leveraging technology to enhance partner success. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments |
||
| 17.04.25 05:45:00 | Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results | |
| Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. Full year guidance met, with liquidity significantly improved Priority Reset on track to deliver annualised recurring gross savings of € 40 m 2025 guidance: group revenues to grow 5 - 10 % (€ 840 - 880 m); 2028 outlook foresees revenue CAGR2024-2028 between 8 - 12% and generation of EBITDA margin above 20 % HAMBURG, GERMANY / ACCESS Newswire / April 17, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "Evotec's ambitious new direction paves the way for sustainable profitable long-term growth. We are refocusing Evotec on its core strengths: technology and science leadership, where we deliver maximum impact for customers and patients. By combining cutting-edge technology platforms, disruptive science, and AI-driven innovation, we are accelerating the journey from concept to cure with our partners. We delivered on 2024 financial guidance, and I am excited about the opportunities that lie ahead of us. Together with our talented teams, we are writing the next chapter of Evotec's success story as a drug discovery pioneer." Evotec unveils new strategy to refocus on core strengths and define clear roadmap to sustainable profitable growth Technology and science leadership - refocusing on our strong, unique heritage Two pillars: Drug Discovery & Pre-clinical Development (Shared R&D) and Just - Evotec Biologics Drug Discovery & Pre-clinical Development will leverage automation, industrialisation, next generation platforms and AI to accelerate our customers journey and to increase their success rates Business model simplified: focus on high-value services and therapeutic areas, asset portfolio streamlined by ~30 %, R&D supporting next-generation technology development. Exiting equity participations Just - Evotec Biologics growth underpinned by existing partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider, anticipating pivot to an asset lighter model Beating market growth via our scientific and operational expertise, focus, and differentiated technology Commitment to operational excellence for a step-change in performance. Driving operational leverage through our backbone with higher focus on automation. Anchored cost-out initiatives via refined footprint, optimised COGS and SG&A delivering > € 50 m gross savings by 2028 on top of Priority Reset (€ 40 m) Story Continues 2024 revenue and EBITDA within guidance. Priority Reset on track. Q4: Second highest quarterly revenues ever amid challenging market environment Group revenues increased by 2 % to € 797.0 m (2023: € 781.4 m); Q4 2024 revenues increased by 10 % to € 221.2 m from € 201.3 m in Q4 2023 Evotec's Just - Evotec Biologics segment saw impressive growth, with revenues rising by 71 % year-over-year, contributing € 185.6 m (2023: € 108.4 m) to the overall topline Total Shared R&D revenues decreased by 9 % to € 611.4 m (2023: € 673.0 m); Demand still affected by temporary Pharma restructuring and selective funding for Biotech Adjusted Group EBITDA totalled € 22.6 m (2023: € 66.4 m) driven by a mismatch between revenues and cost base in the Shared R&D segment Priority Reset on track to secure an annualised adjusted EBITDA improvement of over € 40 m. One-off costs recognised at € 54.9 m, vs. initial provision of € 68.5 m Net debt leverage ratio significantly improved to 1.9x net debt / EBITDA Strengthened partnerships in 2024 paving the way for 2025 growth in soft market environment Group revenue growth expected to accelerate vs. 2024, driven by Just - Evotec Biologics, while Shared R&D revenues expected to remain around 2024 levels Tariffs & US government funding development are expected to have a limited impact on Evotec's business Expansion of technology partnership with Sandoz and new customers for long-term development and commercial manufacturing in Biologics Progress and extension of multi-year collaboration with Bristol Myers Squibb ("BMS") in neuroscience and targeted protein degradation New technology development partnership with Novo Nordisk to support next-generation cell therapies New multi-year master research collaboration with Pfizer, initially focusing on early discovery research for metabolic and infectious diseases Guidance for full-year 2025 Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m) R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m) Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m) Outlook 2028 Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 % Adj. EBITDA margin 2028 expected to be above 20 % CAGR: Compound annual growth rate More detailed information and financial tables are available in the annual report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications Webcast/Conference Call The Company plans to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Thursday, 17 April 2025 Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications. Conference call details To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialling in via phone is available under this link. About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking-statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG volker.braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 10.04.25 10:00:00 | Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 | |
| HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025. The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The conference call will be held in English. Webcast details Date: Thursday, 17 April 2025 Time: 2.00 pm CEST (1.00 pm BST, 8.00 am ET) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: www.evotec.com. Conference call details To join via phone, please pre-register via this link . You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link . About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Story Continues For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
